Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) and Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.
Volatility and Risk
Cartesian Therapeutics has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500.
Institutional and Insider Ownership
86.9% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 37.2% of Cartesian Therapeutics shares are held by insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Cartesian Therapeutics and Sarepta Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cartesian Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
| Sarepta Therapeutics | 8 | 6 | 7 | 0 | 1.95 |
Cartesian Therapeutics presently has a consensus target price of $32.60, indicating a potential upside of 410.17%. Sarepta Therapeutics has a consensus target price of $22.59, indicating a potential upside of 17.83%. Given Cartesian Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Cartesian Therapeutics is more favorable than Sarepta Therapeutics.
Earnings and Valuation
This table compares Cartesian Therapeutics and Sarepta Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cartesian Therapeutics | $1.48 million | 130.89 | -$130.30 million | ($5.94) | -1.08 |
| Sarepta Therapeutics | $2.20 billion | 0.92 | -$713.41 million | ($2.90) | -6.61 |
Cartesian Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Cartesian Therapeutics and Sarepta Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cartesian Therapeutics | -8,550.65% | N/A | -29.84% |
| Sarepta Therapeutics | -13.48% | -1.60% | -0.66% |
Summary
Cartesian Therapeutics beats Sarepta Therapeutics on 9 of the 14 factors compared between the two stocks.
About Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
